Regulus Therapeutics Ownership | Who Owns Regulus Therapeutics?

Regulus Therapeutics Ownership Summary

Regulus Therapeutics is owned by 86.65% institutional investors, 1.69% insiders, and 11.66% retail investors. Federated hermes is the largest institutional shareholder, holding 44.71% of RGLS shares. Federated Hermes Kaufmann R is the top mutual fund, with 12.04% of its assets in Regulus Therapeutics shares.

RGLS Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Regulus Therapeutics	86.65%	1.69%	11.66%
Sector	Healthcare Stocks	49.73%	8.84%	41.43%
Industry	Biotech Stocks	47.04%	8.74%	44.21%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Federated hermes	12.85M	44.71%	$22.94M
Vanguard group	4.05M	14.09%	$7.23M
Blackrock	3.97M	13.81%	$7.08M
Ra capital management	6.25M	9.70%	$11.16M
Vivo capital	5.00M	7.76%	$8.93M
Fmr	2.02M	7.04%	$3.61M
Octagon capital advisors lp	4.26M	6.61%	$7.61M
Deep track capital, lp	3.26M	5.06%	$5.82M
Geode capital management	1.33M	4.64%	$2.38M
Millennium management	1.22M	4.23%	$2.17M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Octagon capital advisors lp	4.26M	1.20%	$7.61M
Vivo capital	5.00M	0.82%	$8.93M
Cvi	401.01K	0.62%	$715.81K
Opaleye management	1.48M	0.60%	$2.63M
Dafna capital management	895.20K	0.38%	$1.60M
Deep track capital, lp	3.26M	0.17%	$5.82M
Ra capital management	6.25M	0.15%	$11.16M
Sarissa capital management lp	185.18K	0.06%	$330.55K
Federated hermes	12.85M	0.05%	$22.94M
Monashee investment management	197.05K	0.05%	$351.73K

Top Buyers

Holder	Shares	% Assets	Change
Octagon capital advisors lp	4.26M	1.20%	4.26M
Blackrock	3.97M	0.00%	3.90M
Vanguard group	4.05M	0.00%	3.31M
Opaleye management	1.48M	0.60%	1.30M
Geode capital management	1.33M	0.00%	1.17M

Top Sellers

Holder	Shares	% Assets	Change
Adage capital partners gp	2.00M	0.01%	-1.68M
Soleus capital management	-	-	-1.56M
Cvi	401.01K	0.62%	-1.01M
Fmr	2.02M	0.00%	-900.00K
Millennium management	1.22M	0.00%	-659.64K

New Positions

Holder	Shares	% Assets	Change	Value
Octagon capital advisors lp	4.26M	1.20%	4.26M	$7.61M
Woodline partners lp	947.68K	0.02%	947.68K	$1.69M
Bank of new york mellon	197.19K	0.00%	197.19K	$351.99K
Charles schwab investment management	178.88K	0.00%	178.88K	$319.30K
Nuveen asset management	85.60K	-	85.60K	$152.80K

Sold Out

Holder	Change
Parallel advisors	-10.00
Macquarie group	-865.00
Tower research capital llc (trc)	-3.21K
Group one trading	-8.61K
Prelude capital management	-14.10K

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Sep 30, 2024	74	13.85%	56,730,064	3.44%	86	1.20%	36	-10.00%	15	-6.25%
Jun 30, 2024	65	38.30%	54,841,329	20.21%	85	1.70%	40	11.11%	16	300.00%
Mar 31, 2024	47	88.00%	45,620,979	398.54%	70	35.12%	36	260.00%	4	-
Dec 31, 2023	25	4.17%	9,150,867	2.37%	14	7.38%	10	11.11%	4	-20.00%
Sep 30, 2023	24	4.35%	8,938,928	8.86%	13	8.55%	9	-18.18%	5	400.00%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Federated Hermes Kaufmann R	7.88M	12.04%	-
Federated Hermes Kaufmann Small Cap A	7.42M	11.33%	-
Federated Hermes Kaufmann Small Cap Grow	2.96M	4.53%	-450.00K
Federated Hermes Kaufmann Growth	2.68M	4.09%	-505.00K
Vanguard Total Stock Mkt Idx Inv	2.50M	3.82%	-
iShares Russell 2000 ETF	1.74M	2.66%	-3.64K
T. Rowe Price Health Sciences	1.68M	2.57%	1.68M
Victory Science & Technology	1.54M	2.34%	126.95K
Vanguard Institutional Extnd Mkt Idx Tr	940.39K	1.44%	-190.41K
Fidelity Small Cap Index	644.44K	0.98%	-8.74K

Recent Insider Transactions

Date	Name	Role	Activity	Value
Jul 25, 2024	Collier Kathryn J	-	Buy	$7.28K
Jan 18, 2024	CALSADA CRISPINA	Chief Financial Officer	Sell	$6.51K
Jan 18, 2024	Aker Christopher Ray	Sr. VP & General Counsel	Sell	$6.51K
Jan 18, 2024	Hagan Joseph P	Chief Executive Officer	Sell	$17.36K
Mar 01, 2022	Drygin Denis	Chief Scientific Officer	Buy	$17.64K

Insider Transactions Trends

Date	Buy	Sell
2024 Q2	-	-
2024 Q1	-	3
2023 Q3	-	-
2023 Q2	-	-
2023 Q1	-	-

RGLS Ownership FAQ

Who Owns Regulus Therapeutics?

Regulus Therapeutics shareholders are primarily institutional investors at 86.65%, followed by 1.69% insiders and 11.66% retail investors. The average institutional ownership in Regulus Therapeutics's industry, Biotech Stocks , is 47.04%, which Regulus Therapeutics exceeds.

Who owns the most shares of Regulus Therapeutics?

Regulus Therapeutics’s largest shareholders are Federated hermes (12.85M shares, 44.71%), Vanguard group (4.05M shares, 14.09%), and Blackrock (3.97M shares, 13.81%). Together, they hold 72.61% of Regulus Therapeutics’s total shares outstanding.

Does Blackrock own Regulus Therapeutics?

Yes, BlackRock owns 13.81% of Regulus Therapeutics, totaling 3.97M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 7.08M$. In the last quarter, BlackRock increased its holdings by 3.9M shares, a 5733.89% change.

Who is Regulus Therapeutics’s biggest shareholder by percentage of total assets invested?

Octagon capital advisors lp is Regulus Therapeutics’s biggest shareholder by percentage of total assets invested, with 1.20% of its assets in 4.26M Regulus Therapeutics shares, valued at 7.61M$.

Who is the top mutual fund holder of Regulus Therapeutics shares?

Federated Hermes Kaufmann R is the top mutual fund holder of Regulus Therapeutics shares, with 12.04% of its total shares outstanding invested in 7.88M Regulus Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools